Isomorphic Labs Raises $2.1 Billion for AI Drug Discovery
Isomorphic Labs, an AI-driven drug discovery company led by DeepMind CEO Demis Hassabis, secured $2.1 billion in Series B funding. The investment, led by Thrive Capital, will support the expansion of their AI drug design engine and the development of new therapeutic candidates, highlighting strong confidence in their innovative disease treatment approach.
The Economic Times·


